Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.

Eli Lilly trades at a rich P/E of 46 and a 0.6% dividend yield after 2025 revenue was driven by GLP‑1s—Mounjaro sales rose 99% and Zepbound sales jumped 175% in 2025. Novo Nordisk, by comparison, saw obesity‑drug growth of 31% in 2025, trades at a P/E of 13 with a 3.9% yield and a ~40% payout ratio, but warned a U.S. pricing agreement will pressure 2026 results (stock down ~66% since mid‑2024) while expecting improvement in 2027. Pfizer (P/E ~20) is pursuing partnerships and M&A after an internal GLP‑1 failure, yields ~6.3% with a payout ratio above 100%, and is leaning on oncology and migraine R&D; the piece frames Novo and Pfizer as potential contrarian/value/dividend plays versus growth‑focused Lilly.

Analysis

Market structure: Eli Lilly (LLY) is the incumbent GLP‑1 growth winner and has pulled forward pricing power (LLY P/E ~46) while Novo Nordisk (NVO, P/E ~13) and Pfizer (PFE, P/E ~20) trade like beaten incumbents. Winners: LLY (market share, premium multiple) and innovators with scalable oral GLP‑1s; losers short term: NVO and PFE equity holders and suppliers exposed to sudden volume reallocation. Supply/demand: patient demand for GLP‑1s remains structurally strong; Novo’s oral pill expands addressable market (meaningful TAM upside into 2027) while manufacturing scale and raw peptide inputs could become bottlenecks in 6–18 months. Cross‑asset: pharma equity outflows may push investors into higher yielding IG credit and sovereign bonds; implied vol on NVO/PFE will stay elevated near earnings/regulatory dates and DKK/USD FX moves could add noise to NVO ADR flows.

Risks: tail risks include US pricing/regulatory caps, class safety signals, and a Pfizer dividend cut if FCF stays negative (payout >100% now) — probability medium but impact high within 6–12 months. Hidden dependencies: payer formularies, pharmacy benefit manager (PBM) negotiations, and manufacturing scale‑up timelines drive real revenue in 2027, not 2026. Catalysts: NVO 2027 guidance updates, FDA label decisions for oral GLP‑1s, Pfizer M&A/partner announcements, and quarterly FCF prints across next 4 quarters.

Trade implications: direct longs in NVO for value+income (target 40–60% upside over 12–24 months) and cautious long PFE for yield with downside protection; avoid naked long on LLY at current multiple. Pair trade (long NVO, short LLY) exploits multiple compression; options play: buy 12–24 month LEAPS on NVO 20% OTM to capture pill optionality and sell covered calls after a 25% move up. Rotate 2–5% portfolio weight from high‑multiple growth healthcare into beaten‑down high‑yield pharma and IG credit over next 2–8 weeks.

Contrarian angles: the market underweights Novo’s oral GLP‑1 optionality — a successful pill rollout in 2027 could re‑rate NVO from P/E 13 toward 20+ as TAM expands. The selloff may be overdone: 66% drawdown since mid‑2024 implies pricing in sustained reimbursement collapse; historical parallels (post‑policy selloffs in pharma) suggest rebounds once visibility on payer access improves. Unintended consequence: aggressive payer restrictions could compress all GLP‑1 pricing, making relative picks hinge on manufacturing cost advantages and label breadth rather than current multiples.

Key Decisions for Investors

• Establish a 2–4% long position in NVO within the next 2–6 weeks (basis: P/E ~13, 3.9% yield, 40% payout ratio). Target +40–60% upside over 12–24 months; place a stop‑loss at -20% or trim if 2027 guidance is cut >15% or dividend is reduced.
• Initiate a 1–2% position in PFE using downside protection: buy shares and hedge with a 6–12 month 10% OTM put or sell cash‑secured puts 5–10% below spot to collect premium. Rationale: 6.3% yield but payout risk; exit/close hedge if two consecutive quarters show FCF insufficient to cover dividend.
• Implement a pair trade: long NVO vs short LLY sized 1:0.5 (long notional : short notional) over a 12‑month horizon to capture multiple mean reversion. Close if LLY reports >50% organic GLP‑1 growth or if NVO’s 2027 outlook misses by >10%.
• Buy 12–24 month NVO LEAPS (20% OTM) equal to 0.5–1% of portfolio to capture upside from oral GLP‑1 adoption; fund by selling 6–9 month covered calls after a 25% rally.
• Rotate 2–5% of portfolio from high‑multiple healthcare (LLY overweight) into beaten‑down high‑yield pharma equities and IG credit over the next 4–8 weeks; re‑evaluate after NVO 2027 guidance and next two quarters of PFE FCF prints.